{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:05Z","timestamp":1790245565621,"version":"4.1.0"},"reference-count":67,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Azienda Ospedaliero-Universitaria of Modena","award":["419"],"award-info":[{"award-number":["419"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Despite the introduction of novel therapeutic options, the prognosis of advanced endometrial cancer remains poor. In recent years, increasing attention has been directed toward the molecular characterization of endometrial cancer. However, data specifically focusing on advanced-stage disease are still limited. In our single-center, retrospective, exploratory study with a limited sample size, we analyzed 32 patients with advanced or recurrent endometrial cancer treated at the Modena Cancer Center. Comprehensive molecular profiling was performed to assess DNA mutations, copy number variations, and RNA expression. We characterized the molecular landscape of this cohort, evaluated selected genomic alterations across predefined clinical subgroups, and explored their association with overall survival. Consistent with previous reports, a high prevalence of PTEN and PIK3CA mutations were observed. Patients experiencing relapse more than six months after diagnosis were more likely to harbor CTNNB1 mutations. KRAS mutations were more frequently detected in younger patients and in those with endometrioid histology, whereas PPP2R1A and TP53 mutations were enriched in tumors with non-endometrioid histology. Notably, CTNNB1 mutations were associated with a favorable prognostic impact, while KRAS mutations correlated with poorer overall survival. Our findings underscore the need for further investigation into the molecular landscape of advanced endometrial cancer, particularly in the context of therapeutic implications. Combinatorial treatment strategies targeting specific molecular alterations, such as KRAS, in combination with other targeted agents or therapeutic approaches, warrant further exploration.<\/jats:p>","DOI":"10.3390\/ijms27021096","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:16:59Z","timestamp":1769159819000},"page":"1096","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Landscape of Advanced Endometrial Cancer: Exploratory Analyses at Modena Cancer Center (MEMO)"],"prefix":"10.3390","volume":"27","author":[{"given":"Marta","family":"Pirola","sequence":"first","affiliation":[{"name":"Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2068-0299","authenticated-orcid":false,"given":"Eleonora","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Oncology Area Sud AUSL Modena, Ospedale of Sassuolo, 41049 Sassuolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Manfredini","sequence":"additional","affiliation":[{"name":"Division of Molecular Pathology and Predictive Medicine, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cuoghi Costantini","sequence":"additional","affiliation":[{"name":"Statistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Carlucci","sequence":"additional","affiliation":[{"name":"Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7224-4536","authenticated-orcid":false,"given":"Claudia","family":"Piombino","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pipitone","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Vitale","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bacchelli","sequence":"additional","affiliation":[{"name":"Clinical Trials Office, Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Botticelli","sequence":"additional","affiliation":[{"name":"Department of Pathology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Eccher","sequence":"additional","affiliation":[{"name":"Department of Pathology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Statistics Unit, Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Longo","sequence":"additional","affiliation":[{"name":"Oncology Area Sud AUSL Modena, Ospedale of Sassuolo, 41049 Sassuolo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bettelli","sequence":"additional","affiliation":[{"name":"Division of Molecular Pathology and Predictive Medicine, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3051-8057","authenticated-orcid":false,"given":"Cinzia","family":"Baldessari","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[{"name":"Division of Oncology, University of Modena and Reggio Emilia, 41124 Modena, Italy"},{"name":"Division of Oncology, Department of Oncology & Hematology, Azienda Ospedaliero-Universitaria of Modena, 41124 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Galant, N., Krawczyk, P., Monist, M., Obara, A., Gajek, \u0141., Grenda, A., Nico\u015b, M., Kalinka, E., and Milanowski, J. (2024). Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25115893"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guide-line for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.2012.48.2596","article-title":"Type I and II Endometrial Cancers: Have They Different Risk Factors?","volume":"31","author":"Setiawan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, and Levine, D.A. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373. Erratum in Nature 2013, 500, 242. https:\/\/doi.org\/10.1038\/nature12325.","DOI":"10.1038\/nature12113"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2024.01.044","article-title":"Evaluation of prognostic potential of \u03b2-catenin and L1CAM expression according to endometrial cancer risk group","volume":"184","author":"Yoon","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ygyno.2023.04.018","article-title":"Adjuvant radiation therapy in early-stage endometrial cancer with abnormal beta-catenin expression is associated with improved local control","volume":"174","author":"Hui","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ajcp\/aqy178","article-title":"Immunohistochemical Nuclear Expression of \u03b2-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer","volume":"151","author":"Travaglino","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Santoro, A., Arciuolo, D., Travaglino, A., Inzani, F., Zannoni, G.F., Raffone, A., and Mollo, A. (2022). Immunohistochemical Assessment of \u03b2-Catenin in Endometrial Carcinoma. Am. J. Clin. Pathol., 157.","DOI":"10.1093\/ajcp\/aqab207"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"POR-TEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"Horeweg","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitax-el\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in ad-vanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gore.2019.04.002","article-title":"Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience","volume":"28","author":"Rubinstein","year":"2019","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: The PARAGON trial\u2014ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin\u2013paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bartoletti, M., Montico, M., Lorusso, D., Mazzeo, R., Oaknin, A., Musacchio, L., Scambia, G., Puglisi, F., and Pignata, S. (2024). Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis. Cancer Treat. Rev., 125.","DOI":"10.1016\/j.ctrv.2024.102701"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in Patients with Microsatellite Instability\u2013High Advanced Endometrial Cancer: Results from the KEYNOTE-158 Study","volume":"40","author":"Bariani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Andr\u00e9, T., Berton, D., Curigliano, G., Sabatier, R., Tinker, A.V., Oaknin, A., Ellard, S., de Braud, F., Arkenau, H.T., and Trigo, J. (2023). Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients with Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Netw. Open, 6.","DOI":"10.1001\/jamanetworkopen.2023.41165"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib Plus Pembrolizumab in Patients with Advanced Endometrial Cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102790","DOI":"10.1016\/j.ctrv.2024.102790","article-title":"Locally advanced and metastatic endometrial cancer: Current and emerging therapies","volume":"129","author":"Salmon","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bredin, H.K., Krakstad, C., and Hoivik, E.A. (2023). PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0283203"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II Study of Everolimus and Letrozole in Patients with Recurrent Endometrial Carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ygyno.2024.02.029","article-title":"Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity","volume":"183","author":"Passarelli","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1634\/theoncologist.2015-0149","article-title":"The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer","volume":"20","author":"Diver","year":"2015","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cham, S., Xiong, N., Tayob, N., Krasner, C., Wright, A.A., Lee, E.K., Sawyer, H., Mathews, C., Konstantinopoulos, P.A., and Matulonis, U.A. (2025). Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma. Gynecol. Oncol. Rep., 60.","DOI":"10.1016\/j.gore.2025.101796"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.21873\/invivo.11524","article-title":"The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated with Pathogenesis and Cancer Progression","volume":"33","author":"Toumpeki","year":"2019","journal-title":"Vivo"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/mc.23308","article-title":"Inhibiting Wnt\/beta-catenin in CTNNB1-mutated endometrial cancer","volume":"60","author":"Moroney","year":"2021","journal-title":"Mol. Carcinog."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-17-0342","article-title":"TTK Inhibitors as a Targeted Therapy for CTNNB1 (\u03b2-catenin) Mutant Cancers","volume":"16","author":"Zaman","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Fatima, I., Barman, S., Rai, R., Thiel, K.W.W., and Chandra, V. (2021). Targeting Wnt Signaling in Endometrial Cancer. Cancers, 13.","DOI":"10.3390\/cancers13102351"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/bjc.2012.477","article-title":"KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer","volume":"107","author":"Birkeland","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ygyno.2024.10.026","article-title":"KRAS mutations in endometrial cancers: Possible prognostic and treatment implications","volume":"191","author":"Kilowski","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/IGC.0000000000000960","article-title":"Endometrial Cancers With Activating KRas Mutations Have Activated Estrogen Signaling and Paradoxical Response to MEK Inhibition","volume":"27","author":"Ring","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1038\/s41388-025-03539-1","article-title":"ARID1A: Gene, protein, and function in endometrial cancer","volume":"44","author":"LaBuda","year":"2025","journal-title":"Oncogene"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Szyma\u0144ski, M., Jerka, D., Bonowicz, K., Antosik, P., and Gagat, M. (2025). Assessment of Cyclin D1 Expression: Prognostic Value and Functional Insights in Endometrial Cancer: In Silico Study. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26030890"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00404-021-06385-0","article-title":"Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: A systematic review and meta-analysis","volume":"306","author":"Travaglino","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Di Fiore, R., Suleiman, S., Drago-Ferrante, R., Subbannayya, Y., Suleiman, S., Vasileva-Slaveva, M., Yordanov, A., Pentimalli, F., Giordano, A., and Calleja-Agius, J. (2023). The Role of FBXW7 in Gynecologic Malignancies. Cells, 12.","DOI":"10.3390\/cells12101415"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2017.02.031","article-title":"FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Jeske","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Khatun, M., Pasanen, A., Kanerva, A., Koivisto-Korander, R., Tuomi, T., B\u00fctzow, R., and Loukovaara, M. (2025). PPP2R1A mutation status as a predictive and prognostic factor in molecularly characterized endometrial carcinoma: A cohort study. Int. J. Gynecol. Cancer, 35.","DOI":"10.1016\/j.ijgc.2025.101934"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1389450114666140106100909","article-title":"Therapeutic Targeting of Cancers with Loss of PTEN Function","volume":"15","author":"Dillon","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s13193-022-01523-9","article-title":"Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation","volume":"13","author":"Tresa","year":"2022","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/ijgc-2021-003340","article-title":"Adjuvant treatment in early-stage endometrial cancer: Context-dependent impact of somatic CTNNB1 mutation on recurrence-free survival","volume":"32","author":"Kurnit","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/mc.20850","article-title":"PPP2R1A mutations are common in the serous type of endometrial cancer","volume":"51","author":"Nagendra","year":"2012","journal-title":"Mol. Carcinog."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/annonc\/mdv142","article-title":"Anthropometric factors and endometrial cancer risk: A systematic review and dose\u2013response meta-analysis of prospective studies","volume":"26","author":"Aune","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1200\/JCO.2016.69.4638","article-title":"Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment","volume":"34","author":"Onstad","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Lopez-Janeiro, A., Brizzi, E., Ruz-Caracuel, I., Alexandru, R., de Andrea, C., Berj\u00f3n, A., Yebenes, L., Mendiola, M., Heredia-Soto, V., and Montero-Calle, A. (2025). The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas. Cells, 14.","DOI":"10.20944\/preprints202509.1678.v1"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/1442441","article-title":"The Role of CTNNB1 in Endometrial Cancer","volume":"2022","author":"Ledinek","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Penick, E., Tian, C., Bateman, N., Oliver, J., Mitchell, D., Conrads, T., Hamilton, C., Maxwell, G., and Darcy, K. (2017). CTNNB1 predicts better progression-free survival in endometrioid endometrial cancer patients treated with chemotherapy. Gynecol. Oncol., 145.","DOI":"10.1016\/j.ygyno.2017.03.191"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/gyno.1996.0313","article-title":"K-rasPoint Mutations in Endometrial Carcinoma: Effect on Outcome Is Dependent on Age of Patient","volume":"63","author":"Ito","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/S0959-8049(97)00154-8","article-title":"The Clinicopathological Significance of K-RAS Point Mutation and Gene Amplification in Endometrial Cancer","volume":"33","author":"Esteller","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.2217\/fon-2021-0650","article-title":"Age-Dependent Prognostic Value of KRAS Mutation in Metastatic Colorectal Cancer","volume":"17","author":"Ozer","year":"2021","journal-title":"Futur. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Vestergaard, L.K., Oliveira, D.N.P., Poulsen, T.S., H\u00f8gdall, C.K., and H\u00f8gdall, E.V. (2021). Oncomine\u2122 Comprehensive Assay v3 vs. Oncomine\u2122 Comprehensive Assay Plus. Cancers, 13.","DOI":"10.3390\/cancers13205230"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: The Human Genomic Variant Search Engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_65","unstructured":"Qiagen Digital Insights (2022, August 29). Franklin by Qiagen. Available online: https:\/\/digitalinsights.qiagen.com\/franklin\/."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Li, Q., Ren, Z., Cao, K., Li, M.M., Wang, K., and Zhou, Y. (2022). CancerVar: An Artificial Intelligence\u2013Empowered Platform for Clinical Interpretation of Somatic Mutations in Cancer. Sci. Adv., 8.","DOI":"10.1126\/sciadv.abj1624"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/1096\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:20:10Z","timestamp":1769160010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/1096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":67,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27021096"],"URL":"https:\/\/doi.org\/10.3390\/ijms27021096","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}